Sarah Sammons, MD, discusses findings from an analysis of the DESTINY-Breast03 trial regarding trastuzumab deruxtecan vs ...

Additionally, the study did not establish the efficacy of T-Duo in patients previously treated with trastuzumab deruxtecan. This study was supported by Byondis B.V. Co-authors Evelyn van den Tweel ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

After chemotherapy failure, if the cancer is also resistant to endocrine therapy, patients face a double obstacle: few ...

NPPA asks companies to revise MRP of three anti-cancer drugs and submit information: Gireesh Babu, New Delhi Tuesday, October 29, 2024, 16:15 Hrs [IST] The National Pharmaceutical ...

After custom duty exemption and a reduction in GST rates, the National Pharmaceutical Pricing Authority (NPPA) has now ...

and AZ/Daiichi Sankyo's Enhertu (trastuzumab deruxtecan). That is down to the company's ADC technology platform, which means that the cytotoxic payload that circulates systemically after ...

But of course we now know that many of these drugs, including drugs like T-DM1 and trastuzumab deruxtecan (T-DXd), do lead to CNS responses. So enough is getting in that we're seeing a biological ...

You've just been diagnosed with HER2+ breast cancer, and you're wondering what happens next. Every person is different, but here’s what treatment generally looks like and what milestones you can ...

Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase ...